Thyroid profile as a marker of poor prognostic factor in patients with acute coronary syndrome: a tertiary care hospital based observational study

Navaraj Paudel, Madhav Alurkar, Ramchandra Kafle, Abhishek Maskey, Subash Sapkota

Department of Cardiology, Manipal Teaching Hospital, Pokhara, Nepal.

Corresponding Author: Navaraj Paudel, MCOMS-MTH, Phulhari-11, Pokhara, Kashi, Nepal. Email: drnavarajdm@gmail.com

Abstract
Background and aims: Serum thyroid hormonal changes can occur in acute or chronic non-thyroidal systemic illness including acute coronary syndrome in otherwise euthyroid individuals. In this study we aimed to assess thyroid hormonal profile in patients presenting with acute coronary syndromes (ACS) and compare between ST segment elevated myocardial infarction and unstable angina/Non ST segment elevated myocardial infarction.

Methods: A hospital based, retrospective, observational comparative study was designed. Data of all patients with acute coronary syndrome presenting to hospital were collected from July 2015 through June 2017 in a pre-structured proforma and analyzed.

Results: A total of 200 ACS patients between 23 years to 88 years with mean age of 61.33 ± 12.30 years were studied. One hundred and twenty seven (63.5%) were males. Among them 116 (58%) was ST segment elevated myocardial infarction (STEMI) patients while 84 (42%) were unstable angina/ non-ST elevated myocardial infarction (UA/NSTEMI) patients. Total 47 (23.5%) patients had abnormal TFT of which 28(59.5%) had Euthyroid Sick Syndrome, 12(25.5%) had subclinical hypothyroidism, 5(10.6%) had subclinical hyperthyroidism and 2(4.25%) had low fT4 with normal fT3 and normal TSH. There was significant difference in TFT in patients with STEMI and UA/NSTEMI (P=0.006). There were higher rates of heart failure (p= 0.001 & 0.003 in STEMI & UA/NSTEMI respectively), longer length of hospital stay (3±0.17 days) and high mortality (more than 4 fold) in all types of ACS patients with abnormal TFT than ACS patients with normal TFT.

Conclusion: There is higher prevalence of abnormal thyroid hormonal findings in ACS causing significant morbidity and mortality.

Keywords: Acute coronary syndrome, prognosis, thyroid hormone profile.

DOI: http://dx.doi.org/10.3126/njh.v15i1.19715

Introduction
Alteration in the level of serum thyroid hormone profile has been described in several non-thyroidal systemic illnesses including acute heart diseases in otherwise euthyroid patients. This condition has been termed as “Euthyroid Sick Syndrome” and is characterized by decreased serum T3 and/or free T3, increased serum reverse T3 (rT3), plus normal serum TSH, T4, and free T4 levels. Patients belonging to the STEMI group showed early elevations, in addition to higher mean reverse T3 (rT3) and lower mean T3 and free T3 levels. This syndrome has been reported to be found in severe chronic heart failure, acute myocardial infarction and as a rapidly emerging phenomenon during open-heart surgery. Additionally hypothyroidism is emerging as a risk for coronary artery disease.

Evaluation of thyroid hormone plasma levels has been done in a number of studies in patients presenting with Acute Coronary Syndrome (ACS) and findings compared between Unstable Angina/Non-ST elevation MI (UA/NSTEMI) and ST Elevation acute MI (STEMI) groups. Some studies have reported association of greater hormonal changes with more severe cardiac events (STEMI and Death) and patients with complications.

An association of Euthyroid sick syndrome in ACS with poorer prognosis has been suggested in few studies. It has further been stated that the euthyroid sick syndrome has special significance in patients of ACS because low T3 levels in these patients signify severe disease and can be used as a marker for early invasive management in these patients.

Till date to my knowledge there are no data regarding thyroid profile in ACS patients from this part of world. This study aims to study the thyroid hormone profile in patients of ACS and to compare it in between STEMI and UA/NSTEMI groups.

Methods: This is a hospital based, cross-sectional, comparative, observational study done from July 2015 to June 2017 in the department of cardiology of Manipal Teaching hospital, Nepal. 200 consecutive cases of acute coronary syndromes were taken for the study. Depending on the ECG findings and result of cardiac markers, the patients of ACS were categorized into following two groups as per American Heart Association (AHA) criteria. Group 1 considered cases showing ST depression / T wave inversion with normal or elevated cardiac markers. At the time of presentation, patients with UA and NSTEMI can be indistinguishable and therefore are considered together in these guidelines. UA is defined as angina pectoris or equivalent ischemic discomfort with at least one of three features: (1) it occurs at rest (or with minimal exertion), usually lasting >10 minutes; (2) it is severe and of new onset (i.e., within the prior 4–6 weeks); and/or (3) it occurs with a crescendo pattern (i.e., distinctly more severe, prolonged, or frequent than previously).

The diagnosis of NSTEMI is established if a patient with the clinical features of UA develops evidence of myocardial necrosis, as reflected in elevated cardiac biomarkers and Group 2
Thyroid profile as a marker of poor prognostic factor in patients with acute coronary syndrome: a tertiary care hospital based observational study

Results:
Two hundred ACS patients between 23 years to 88 years with mean age of 61.33 ± 12.30 years were studied. 115 (57.5%) were more than 60 years, 70 (35%) were 40-60 years and 15 (7.5%) belonged to age group of 20-40 years. 127 (63.5%) were males. 116 (58%) were STEMI patients while 84 (42%) were UA/NSTEMI patients. 76 (39%) patients were hypertensive and on medications while only 21 (10.5%) were diabetics. 134 (67%) belonged to age group of 20-40 years. 127 (63.5%) were males. 115 (57.5%) were STEMI patients while 84 (42%) were UA/NSTEMI patients. 76 (39%) patients were hypertensive and on medications while only 21 (10.5%) were diabetics. 134 (67%) belonged to age group of 20-40 years. 127 (63.5%) were males.

Altered
TFT
23%

Table 1: Pattern of abnormal thyroid profile in patients with different categories.

<table>
<thead>
<tr>
<th>Category</th>
<th>No of pts with Euthyroid sick syndrome</th>
<th>No of pts with subclinical hypothyroidism</th>
<th>No of pts with subclinical hyperthyroidism</th>
<th>No of pts with low fT4 but normal fT3 and TSH</th>
<th>Total pts with abnormal TFTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>20</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>35</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>12</td>
</tr>
</tbody>
</table>

Figure 1: Thyroid hormone in pts with ACS

Thyroid hormone analysis was done in all the ACS patients and was found abnormal in 47 (23.5%) of the patients. Out of 127 males and 73 females with ACS, 27 (21.25%) patients had abnormal TFTs while 20 (27.39%) female patients with ACS had abnormal TFTs. There was no statistically significant difference in prevalence of abnormal thyroid hormone profile in males and females with ACS (p=0.35).

Table 2: Comparison of abnormal TFT reports in patients with STEMI and UA/NSTEMI

<table>
<thead>
<tr>
<th>Category</th>
<th>Number of pts with normal TFT reports</th>
<th>Number of pts with abnormal TFT reports</th>
<th>Odds ratio</th>
<th>P-value (Fisher exact probability test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>81</td>
<td>35</td>
<td>2.59</td>
<td>0.006</td>
</tr>
<tr>
<td>UA/NSTEMI</td>
<td>72</td>
<td>12</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Analysis of ACS patients with heart failure and abnormal thyroid

<table>
<thead>
<tr>
<th>Category</th>
<th>TTT reports</th>
<th>Number of patients with heart failure</th>
<th>Number of patients without heart failure</th>
<th>P-value (Fisher exact probability test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>Normal</td>
<td>7</td>
<td>73</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Abnormal</td>
<td>12</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>UA/NSTEMI</td>
<td>Normal</td>
<td>2</td>
<td>70</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Abnormal</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

The above table (table 1) shows that there was significant difference in patients with abnormal TFT reports presenting or having heart failure both in STEMI or UA/NSTEMI groups.

Table 4: Analysis of ACS patients of different thyroid status with average length of hospital stay

<table>
<thead>
<tr>
<th>Category</th>
<th>TTT report</th>
<th>Mean average hospital stay (in days)</th>
<th>Mean difference (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>Normal</td>
<td>6±0.7</td>
<td>-1.0(-3.56 to 2.45)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Abnormal</td>
<td>9±2.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA/NSTEMI</td>
<td>Normal</td>
<td>5±1.1</td>
<td>-2.0(-2.79 to -1.22)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Abnormal</td>
<td>7±2.01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Further analysis in mean average hospital stay and mortality with abnormal thyroid hormone profiles in these patients was analyzed. The mean hospital stay was significantly higher (p=0.001) in both the groups (Table 4). Mortality was slightly higher in patients having abnormal TFT reports but not significant in both the groups (p= 0.164 and 0.1429 respectively) (table 5).

Table 5: Analysis of ACS patients of different thyroid status with average length of hospital stay

<table>
<thead>
<tr>
<th>Category</th>
<th>TTT Report</th>
<th>Number of patients died</th>
<th>Number of patients survived</th>
<th>OR(95% CI)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>Normal</td>
<td>2</td>
<td>78</td>
<td>1.650(583 to 22.928)</td>
<td>0.164</td>
</tr>
<tr>
<td></td>
<td>Abnormal</td>
<td>3</td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA/NSTEMI</td>
<td>Normal</td>
<td>0</td>
<td>72</td>
<td>NA</td>
<td>0.1429</td>
</tr>
<tr>
<td></td>
<td>Abnormal</td>
<td>1</td>
<td>11</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p value obtained from Fischer exact test (2 tailed)
Thyroid profile as a marker of poor prognostic factor in patients with acute coronary syndrome: a tertiary care hospital based observational study

Discussion:
Alteration in the level of serum thyroid hormone profile has been described in various non-thyroidal systemic illnesses including acute heart diseases in otherwise euthyroid patients which is called as “euthyroid sick syndrome”. Present study assesses thyroid profile in ACS and compare between the ACS sub-groups. Our study showed abnormal thyroid hormonal findings in 47(23.5%) of patients with ACS. This result was comparable to various other studies in other part of the world too. For example a study of 400 patients of ACS by Qari FA, thyroid dysfunction was reported in 23.3% of patients. Similarly Khalil OA et al in their study of 196 patients of ACS, reported changes in thyroid hormone profile in 25% of their patients. Mathur P et al in their study of 85 patients and Bayrak A et al in their study of 110 patients of ACS reported changes in thyroid hormone profile in 31.7% and 23.6% of patients respectively.

This study is done to see the status of thyroid profile in patients with ACS in our part of world. Our study showed a higher prevalence of abnormal thyroid hormone profile was seen in patients of STEMI group as compared to NSTE/UA group being 35 out of 47 (74.46%) in STEMI group and 12 out of 47 (25.56%) in NSTE/UA group. The difference is statistically significant (p=0.006). Similarly there was high prevalence of different thyroid patterns like euthyroid sick syndrome, subclinical hypothyroidism or hyperthyroidism and low T4 but normal TSH and T3 in STEMI group than UA/NSTEMI. These results are comparable to studies done before. Thyroid dysfunction in acute coronary syndrome increases the relative risk of death by 5.49 fold than euthyroid patients.

Takada K et al in year 1994 in their study of relationship of thyroid profile and level of troponins.

Limitation:
Cardiac enzymatic levels of troponins (quantitative) were not available in the laboratory of study area. Had it been there we could further compare the relationship with altered thyroid profile and level of troponins.

Conclusion:
There is higher prevalence of abnormal thyroid hormonal findings in ACS causing significant morbidity and mortality. As a future direction, thyroid hormone profile done at the time of admission in patients with ACS may be used as a marker of prognosis along with other established scores or biochemical markers.

References: